Global Myeloproliferative Disorders Drugs Market Size, Status and Forecast 2020-2026

May 2020 | 91 pages | ID: G86A71919EBFEN
QYResearch

Abstracts

This report focuses on the global Myeloproliferative Disorders Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myeloproliferative Disorders Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

• Celgene
• Bristol-Myers Squibb
• Gamida Cell
• Incyte
• Geron
• Promedior
• Johnson and Johnson
• ...

Market segment by Type, the product can be split into

• Ph+ CML
• Ph- MPN

Market segment by Application, split into

• Hospitals
• Pharmacy

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Myeloproliferative Disorders Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Myeloproliferative Disorders Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Myeloproliferative Disorders Drugs are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myeloproliferative Disorders Drugs Revenue
1.4 Market Analysis by Type
  1.4.1 Global Myeloproliferative Disorders Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Ph+ CML
  1.4.3 Ph- MPN
1.5 Market by Application
  1.5.1 Global Myeloproliferative Disorders Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Myeloproliferative Disorders Drugs Market Perspective (2015-2026)
2.2 Myeloproliferative Disorders Drugs Growth Trends by Regions
  2.2.1 Myeloproliferative Disorders Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Myeloproliferative Disorders Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Myeloproliferative Disorders Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Myeloproliferative Disorders Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Myeloproliferative Disorders Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Myeloproliferative Disorders Drugs Players by Market Size
  3.1.1 Global Top Myeloproliferative Disorders Drugs Players by Revenue (2015-2020)
  3.1.2 Global Myeloproliferative Disorders Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Myeloproliferative Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myeloproliferative Disorders Drugs Market Concentration Ratio
  3.2.1 Global Myeloproliferative Disorders Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Myeloproliferative Disorders Drugs Revenue in 2019
3.3 Myeloproliferative Disorders Drugs Key Players Head office and Area Served
3.4 Key Players Myeloproliferative Disorders Drugs Product Solution and Service
3.5 Date of Enter into Myeloproliferative Disorders Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Type (2015-2020)
4.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Type (2021-2026)

5 MYELOPROLIFERATIVE DISORDERS DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
5.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Myeloproliferative Disorders Drugs Market Size (2015-2020)
6.2 Myeloproliferative Disorders Drugs Key Players in North America (2019-2020)
6.3 North America Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
6.4 North America Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Myeloproliferative Disorders Drugs Market Size (2015-2020)
7.2 Myeloproliferative Disorders Drugs Key Players in Europe (2019-2020)
7.3 Europe Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
7.4 Europe Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Myeloproliferative Disorders Drugs Market Size (2015-2020)
8.2 Myeloproliferative Disorders Drugs Key Players in China (2019-2020)
8.3 China Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
8.4 China Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Myeloproliferative Disorders Drugs Market Size (2015-2020)
9.2 Myeloproliferative Disorders Drugs Key Players in Japan (2019-2020)
9.3 Japan Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
9.4 Japan Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Myeloproliferative Disorders Drugs Market Size (2015-2020)
10.2 Myeloproliferative Disorders Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Myeloproliferative Disorders Drugs Market Size (2015-2020)
11.2 Myeloproliferative Disorders Drugs Key Players in India (2019-2020)
11.3 India Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
11.4 India Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Myeloproliferative Disorders Drugs Market Size (2015-2020)
12.2 Myeloproliferative Disorders Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
12.4 Central & South America Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Celgene
  13.1.1 Celgene Company Details
  13.1.2 Celgene Business Overview and Its Total Revenue
  13.1.3 Celgene Myeloproliferative Disorders Drugs Introduction
  13.1.4 Celgene Revenue in Myeloproliferative Disorders Drugs Business (2015-2020))
  13.1.5 Celgene Recent Development
13.2 Bristol-Myers Squibb
  13.2.1 Bristol-Myers Squibb Company Details
  13.2.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  13.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Introduction
  13.2.4 Bristol-Myers Squibb Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
  13.2.5 Bristol-Myers Squibb Recent Development
13.3 Gamida Cell
  13.3.1 Gamida Cell Company Details
  13.3.2 Gamida Cell Business Overview and Its Total Revenue
  13.3.3 Gamida Cell Myeloproliferative Disorders Drugs Introduction
  13.3.4 Gamida Cell Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
  13.3.5 Gamida Cell Recent Development
13.4 Incyte
  13.4.1 Incyte Company Details
  13.4.2 Incyte Business Overview and Its Total Revenue
  13.4.3 Incyte Myeloproliferative Disorders Drugs Introduction
  13.4.4 Incyte Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
  13.4.5 Incyte Recent Development
13.5 Geron
  13.5.1 Geron Company Details
  13.5.2 Geron Business Overview and Its Total Revenue
  13.5.3 Geron Myeloproliferative Disorders Drugs Introduction
  13.5.4 Geron Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
  13.5.5 Geron Recent Development
13.6 Promedior
  13.6.1 Promedior Company Details
  13.6.2 Promedior Business Overview and Its Total Revenue
  13.6.3 Promedior Myeloproliferative Disorders Drugs Introduction
  13.6.4 Promedior Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
  13.6.5 Promedior Recent Development
13.7 Johnson and Johnson
  13.7.1 Johnson and Johnson Company Details
  13.7.2 Johnson and Johnson Business Overview and Its Total Revenue
  13.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Introduction
  13.7.4 Johnson and Johnson Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
  13.7.5 Johnson and Johnson Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Myeloproliferative Disorders Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Myeloproliferative Disorders Drugs Revenue
Table 3. Ranking of Global Top Myeloproliferative Disorders Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myeloproliferative Disorders Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Ph+ CML
Table 6. Key Players of Ph- MPN
Table 7. Global Myeloproliferative Disorders Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Myeloproliferative Disorders Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Myeloproliferative Disorders Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Myeloproliferative Disorders Drugs Market Share by Regions (2015-2020)
Table 11. Global Myeloproliferative Disorders Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Myeloproliferative Disorders Drugs Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Myeloproliferative Disorders Drugs Market Growth Strategy
Table 17. Main Points Interviewed from Key Myeloproliferative Disorders Drugs Players
Table 18. Global Myeloproliferative Disorders Drugs Revenue by Players (2015-2020) (Million US$)
Table 19. Global Myeloproliferative Disorders Drugs Market Share by Players (2015-2020)
Table 20. Global Top Myeloproliferative Disorders Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myeloproliferative Disorders Drugs as of 2019)
Table 21. Global Myeloproliferative Disorders Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Myeloproliferative Disorders Drugs Product Solution and Service
Table 24. Date of Enter into Myeloproliferative Disorders Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 27. Global Myeloproliferative Disorders Drugs Market Size Share by Type (2015-2020)
Table 28. Global Myeloproliferative Disorders Drugs Revenue Market Share by Type (2021-2026)
Table 29. Global Myeloproliferative Disorders Drugs Market Size Share by Application (2015-2020)
Table 30. Global Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 31. Global Myeloproliferative Disorders Drugs Market Size Share by Application (2021-2026)
Table 32. North America Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 34. North America Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 35. North America Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 36. North America Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 37. North America Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 38. Europe Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 40. Europe Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 42. Europe Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 44. China Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 45. China Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 46. China Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 47. China Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 48. China Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 49. China Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 50. Japan Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 52. Japan Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 54. Japan Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 58. Southeast Asia Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 60. Southeast Asia Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 62. India Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 63. India Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 64. India Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 65. India Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 66. India Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 67. India Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Myeloproliferative Disorders Drugs Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Myeloproliferative Disorders Drugs Market Share (2019-2020)
Table 70. Central & South America Myeloproliferative Disorders Drugs Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Myeloproliferative Disorders Drugs Market Share by Type (2015-2020)
Table 72. Central & South America Myeloproliferative Disorders Drugs Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Myeloproliferative Disorders Drugs Market Share by Application (2015-2020)
Table 74. Celgene Company Details
Table 75. Celgene Business Overview
Table 76. Celgene Product
Table 77. Celgene Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 78. Celgene Recent Development
Table 79. Bristol-Myers Squibb Company Details
Table 80. Bristol-Myers Squibb Business Overview
Table 81. Bristol-Myers Squibb Product
Table 82. Bristol-Myers Squibb Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 83. Bristol-Myers Squibb Recent Development
Table 84. Gamida Cell Company Details
Table 85. Gamida Cell Business Overview
Table 86. Gamida Cell Product
Table 87. Gamida Cell Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 88. Gamida Cell Recent Development
Table 89. Incyte Company Details
Table 90. Incyte Business Overview
Table 91. Incyte Product
Table 92. Incyte Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 93. Incyte Recent Development
Table 94. Geron Company Details
Table 95. Geron Business Overview
Table 96. Geron Product
Table 97. Geron Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 98. Geron Recent Development
Table 99. Promedior Company Details
Table 100. Promedior Business Overview
Table 101. Promedior Product
Table 102. Promedior Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 103. Promedior Recent Development
Table 104. Johnson and Johnson Company Details
Table 105. Johnson and Johnson Business Overview
Table 106. Johnson and Johnson Product
Table 107. Johnson and Johnson Revenue in Myeloproliferative Disorders Drugs Business (2015-2020) (Million US$)
Table 108. Johnson and Johnson Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Myeloproliferative Disorders Drugs Market Share by Type: 2020 VS 2026
Figure 2. Ph+ CML Features
Figure 3. Ph- MPN Features
Figure 4. Global Myeloproliferative Disorders Drugs Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Pharmacy Case Studies
Figure 7. Myeloproliferative Disorders Drugs Report Years Considered
Figure 8. Global Myeloproliferative Disorders Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global Myeloproliferative Disorders Drugs Market Share by Regions: 2020 VS 2026
Figure 10. Global Myeloproliferative Disorders Drugs Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global Myeloproliferative Disorders Drugs Market Share by Players in 2019
Figure 13. Global Top Myeloproliferative Disorders Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myeloproliferative Disorders Drugs as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Myeloproliferative Disorders Drugs Revenue in 2019
Figure 15. North America Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America Myeloproliferative Disorders Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Celgene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 23. Celgene Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 24. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Bristol-Myers Squibb Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 26. Gamida Cell Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Gamida Cell Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 28. Incyte Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Incyte Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 30. Geron Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Geron Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 32. Promedior Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Promedior Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 34. Johnson and Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Johnson and Johnson Revenue Growth Rate in Myeloproliferative Disorders Drugs Business (2015-2020)
Figure 36. Bottom-up and Top-down Approaches for This Report
Figure 37. Data Triangulation
Figure 38. Key Executives Interviewed